{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-010602","form_type":"8-K","ticker":"AKTX","cik":"0001541157","company_name":"Akari Therapeutics Plc","filed_at":"2026-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.383503+00:00","generated_at":"2026-05-15T10:24:46.920271+00:00","sec_items":["3.03","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Akari Therapeutics announces 1-for-40 reverse ADS ratio change to meet Nasdaq bid price requirement","bullets":["ADS ratio changes from 1:2,000 to 1:80,000 ordinary shares; each 40 current ADSs become 1 new ADS effective March 31, 2026.","No change to underlying ordinary shares; fractional ADSs will be aggregated and sold with cash proceeds distributed.","Action intended to maintain compliance with Nasdaq minimum bid price requirement for continued listing.","Trading continues on Nasdaq under symbol AKTX; Deutsche Bank will handle the exchange."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-010602","json":"https://secwatch.observer/filing/0001493152-26-010602.json","markdown":"https://secwatch.observer/filing/0001493152-26-010602.md","text":"https://secwatch.observer/filing/0001493152-26-010602.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1541157/000149315226010602/0001493152-26-010602-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1541157/000149315226010602/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T10:24:46.920271+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}